We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





New Method Tested for Early Diagnosis Pediatric Diabetic Nephropathy

By LabMedica International staff writers
Posted on 04 Aug 2016
In type 1 diabetic patients who have progressed to the final stages of nephropathy, kidney failure eventually develops in 50% of individuals within 10 years after the onset of overt nephropathy and in greater than 75% by the 20-year mark.

Nephropathy is diagnosed through the detection of increased urinary albumin excretion, but a growing body of evidence suggests that the risk for developing diabetic nephropathy starts when urinary albumin excretion levels are still within the normal range. More...
If the onset of nephropathy could be detected before urinary albumin rises, patients could potentially be placed on treatment to prevent its development.

A team of scientists at the Aghia Sophia Children’s Hospital (Athens, Greece) has determined that two proteins, growth differentiation factor-15 (GDF-15) and chitinase-3-like protein 1 (YKL-40), could be used to detect diabetic nephropathy early. The team tested 56 type 1 diabetes patients mean age 13.1 ± 3.2 years and 49 healthy controls ages 12.8 ± 6.6 years, for GDF-15 and YKL-40 which were performed by means of immunoenzymatic and immunonephelometric techniques at time of enrollment in the study and after 12 to15 months. Also at these two time points, they evaluated subjects’ kidney function by measuring cystatin C to determine estimated glomerular filtration rate (eGFR) and measuring neutrophil gelatinase associated lipocalin (NGAL).

The teams found that after 12 to 15 months, GDF-15 levels in diabetes patients were significantly higher at 366.7 pg/mL than in healthy controls at 278.6 pg/mL. Initially, no significant difference in YKL-40 measurements was observed between diabetes patients and controls at time of enrollment, but over the course of the study, mean YKL-40 levels in diabetes patients proceeded to increase from 17.4 ng/mL to 20.5 ng/mL. GDF-15 levels also correlated negatively with eGFR values, while YKL-40 levels correlated positively with NGAL and GDF-15, indicating that rises in both proteins reflect a decline in kidney function.

Ioannis Papassotiriou, PhD, the team leader, said, “This is the first study to demonstrate a predictive role for serum GDF-15 and YKL-40 as early markers of diabetic nephropathy in children and adolescents with type 1 diabetes before severe overt nephropathy occurs. Defining new predictors as supplementary tests to urinary albumin excretion for the early diagnosis of diabetic nephropathy could accelerate effective management and treatment approaches needed to minimize the rates of severe renal morbidity and mortality in young patients with type 1 diabetes.”

Related Links:
Aghia Sophia Children’s Hospital


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.